Troriluzole (BHV-4157)

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Obsessive Compulsive Disorder

Conditions

Obsessive Compulsive Disorder

Trial Timeline

Mar 30, 2021 → Feb 13, 2026

NCT ID

NCT04708834

About Troriluzole (BHV-4157)

Troriluzole (BHV-4157) is a phase 3 stage product being developed by Biohaven for Obsessive Compulsive Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT04708834. Target conditions include Obsessive Compulsive Disorder.

What happened to similar drugs?

5 of 9 similar drugs in Obsessive Compulsive Disorder were approved

Approved (5) Terminated (0) Active (4)

✅DuloxetineEli LillyApproved

✅Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)NovartisApproved

✅pregabalin + PlaceboPfizerApproved

✅EscitalopramLundbeckApproved

✅Escitalopram + Placebo oral tabletLundbeckApproved

🔄Fluvoxamine maleate + PlaceboAbbViePhase 3

🔄quetiapine fumarate + SSRI/ClomipramineAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04708834	Phase 3	Terminated	Mar 30, 2021	Feb 13, 2026	Obsessive Compulsive Disorder

Competing Products

17 competing products in Obsessive Compulsive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine	Eli Lilly	Approved	43
Fluvoxamine maleate + Placebo	AbbVie	Phase 3	40
quetiapine fumarate + SSRI/Clomipramine	AstraZeneca	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	35
Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)	Novartis	Approved	43
Bitopertin + Placebo + SSRI	Roche	Phase 2	35
sertraline	Pfizer	Pre-clinical	26
pregabalin + Placebo	Pfizer	Approved	43
Sertraline + Levetiracetam + Placebo	UCB	Phase 2/3	30
Escitalopram	Lundbeck	Approved	36
Escitalopram + Placebo oral tablet	Lundbeck	Approved	44
Valbenazine + Placebo	Neurocrine Biosciences	Phase 2	39
RG1068 (Synthetic Human Secretin)	Repligen	Phase 2	32
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 2/3	32
Nitrous Oxide + Nitrogen	Brain Biotech	Phase 2	32